VK2735 vs Semaglutide
Comparing Viking Therapeutics' dual GLP-1/GIP agonist VK2735 with Novo Nordisk's GLP-1 agonist semaglutide.
Last updated: February 1, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
VK2735
Dossier overview
Semaglutide
Dossier overview
Overview
VK2735 is Viking Therapeutics’ investigational dual GIP/GLP-1 receptor agonist being developed in both injectable and oral formulations. It targets the same receptor combination as tirzepatide, positioning it as a potential competitor in the dual agonist space. Semaglutide remains the established GLP-1 comparator.
Mechanism Comparison
| Aspect | VK2735 | Semaglutide |
|---|---|---|
| Target Receptors | GIP + GLP-1 | GLP-1 only |
| Receptor Activity | Dual agonist | Single agonist |
| Mechanism Class | Same as tirzepatide | GLP-1 analog |
| Developer | Viking Therapeutics | Novo Nordisk |
Dual vs Single Agonism
VK2735 uses the same dual agonist approach as tirzepatide:
- GLP-1: appetite suppression, glucose control
- GIP: enhanced insulin secretion, potential central effects
- Combination may provide superior weight loss
Evidence Comparison
| Aspect | VK2735 | Semaglutide |
|---|---|---|
| Development Phase | Phase 2 | FDA Approved |
| Human Trials | VENTURE program | Extensive |
| Oral Program | Phase 1 | Rybelsus approved |
| Data Maturity | Early | Extensive |
Clinical Trial Data
VK2735 Injectable (Phase 2 - 13 weeks)
| Dose | Weight Loss |
|---|---|
| 2.4mg weekly | ~14.7% |
Context: Short duration, but impressive early results.
VK2735 Oral (Phase 1)
| Observation | Result |
|---|---|
| Weight Loss | ~3.3% (single dose study) |
| Tolerability | Acceptable |
| Oral bioavailability | Demonstrated |
Semaglutide Comparison
| Drug | Trial | Duration | Weight Loss |
|---|---|---|---|
| Semaglutide 2.4mg | STEP 1 | 68 weeks | ~14.9% |
| Oral semaglutide | OASIS 1 | 68 weeks | ~15.1% |
Regulatory Status
| Aspect | VK2735 | Semaglutide |
|---|---|---|
| FDA Status | Investigational | Approved |
| Injectable Phase | Phase 2 | N/A |
| Oral Phase | Phase 1 | Approved (Rybelsus) |
| Expected Timeline | 2026+ | Available now |
Development Strategy
VK2735 Programs
| Formulation | Status | Differentiation |
|---|---|---|
| Injectable | Phase 2 | Dual agonist |
| Oral | Phase 1 | Dual agonist + oral |
Why Oral Dual Agonist Matters
| Factor | Oral VK2735 (potential) | Oral Semaglutide |
|---|---|---|
| Mechanism | GIP + GLP-1 | GLP-1 only |
| Food restrictions | TBD | Yes (fasting) |
| Expected efficacy | Higher (dual) | Proven |
An oral dual agonist would be differentiated from Rybelsus.
Side Effect Profile
| Effect | VK2735 (Early Data) | Semaglutide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| GI tolerability | Being characterized | Well-understood |
| Discontinuation | Low in trials | ~7% |
Competitive Positioning
Dual GIP/GLP-1 Landscape
| Compound | Developer | Status | Differentiator |
|---|---|---|---|
| Tirzepatide | Eli Lilly | Approved | First-in-class |
| VK2735 | Viking | Phase 2 | Smaller, faster |
| Orforglipron | Eli Lilly | Phase 3 | Oral (GLP-1 only) |
VK2735 is behind tirzepatide but could be a fast-follower.
Key Differences
| Factor | VK2735 | Semaglutide |
|---|---|---|
| GIP activity | Yes | No |
| Expected efficacy | Higher (dual) | ~15% |
| Approval status | Investigational | Approved |
| Oral program | Dual agonist | GLP-1 only |
| Company size | Small biotech | Large pharma |
Developer Considerations
| Factor | Viking Therapeutics | Novo Nordisk |
|---|---|---|
| Resources | Limited | Extensive |
| Development speed | Fast for size | Well-funded |
| Partnership potential | Likely needed | N/A |
| Manufacturing | Challenge | Scaled |
Summary
- VK2735 is a dual GIP/GLP-1 agonist showing impressive early weight loss (~15% at 13 weeks)
- Semaglutide is the established GLP-1 agonist with proven efficacy and CV benefit
- Dual agonism (same as tirzepatide) likely confers efficacy advantages
- Oral VK2735 program could differentiate from oral semaglutide
- Viking’s small size may require partnership for full development
This comparison is for educational purposes only. VK2735 is investigational. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.